| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99213 |
Office or other outpatient visit for the evaluation and management of an established patient, low complexity |
34,690 |
28,166 |
$1.24M |
| 99214 |
Office or other outpatient visit for the evaluation and management of an established patient, moderate complexity |
15,121 |
13,204 |
$1.04M |
| 99391 |
Periodic comprehensive preventive medicine reevaluation, established patient, infant (under 1 year) |
6,316 |
5,663 |
$334K |
| 99392 |
Periodic comprehensive preventive medicine reevaluation, established patient, early childhood (1-4 years) |
5,546 |
5,022 |
$282K |
| 99393 |
Periodic comprehensive preventive medicine reevaluation, established patient, late childhood (5-11 years) |
4,645 |
4,187 |
$245K |
| 99394 |
Periodic comprehensive preventive medicine reevaluation, established patient, adolescent (12-17 years) |
2,908 |
2,638 |
$159K |
| 87880 |
Infectious agent antigen detection by immunoassay; Streptococcus, group A |
8,880 |
7,763 |
$106K |
| 99222 |
Initial hospital care, per day, moderate complexity |
1,056 |
972 |
$88K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
2,906 |
2,678 |
$69K |
| 99203 |
Office or other outpatient visit for the evaluation and management of a new patient, low complexity |
802 |
709 |
$48K |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
1,583 |
1,185 |
$44K |
| 54150 |
|
186 |
171 |
$34K |
| 90647 |
|
1,746 |
1,605 |
$24K |
| 90723 |
|
1,900 |
1,752 |
$23K |
| 90670 |
|
1,258 |
1,225 |
$16K |
| 99238 |
Hospital discharge day management, 30 minutes or less |
310 |
283 |
$15K |
| 90707 |
|
1,159 |
1,101 |
$14K |
| 90681 |
|
1,151 |
1,067 |
$14K |
| 87811 |
Infectious agent antigen detection by immunoassay; SARS-CoV-2 (COVID-19) |
393 |
327 |
$14K |
| 90671 |
|
996 |
880 |
$11K |
| 90633 |
|
932 |
869 |
$11K |
| 90716 |
|
797 |
740 |
$10K |
| 87807 |
|
688 |
509 |
$7K |
| 99212 |
Office or other outpatient visit for the evaluation and management of an established patient, straightforward |
154 |
148 |
$4K |
| 90686 |
|
271 |
246 |
$4K |
| 90651 |
|
254 |
238 |
$3K |
| 90734 |
|
245 |
230 |
$3K |
| 96110 |
Developmental screening, with scoring and documentation, per standardized instrument |
571 |
473 |
$2K |
| 87637 |
Infectious agent detection by nucleic acid; SARS-CoV-2, influenza, and RSV |
26 |
17 |
$2K |
| 90700 |
|
164 |
160 |
$2K |
| 96127 |
|
643 |
534 |
$2K |
| 81002 |
|
499 |
433 |
$1K |
| 87502 |
Infectious agent detection by nucleic acid, influenza virus, for multiple types or subtypes, includes all targets |
16 |
12 |
$1K |
| 92587 |
|
22 |
12 |
$1K |
| 90715 |
|
85 |
82 |
$1K |
| 90696 |
|
60 |
60 |
$775.26 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
12 |
12 |
$420.57 |
| 90680 |
|
15 |
15 |
$197.10 |
| 96161 |
|
21 |
16 |
$0.00 |